Suppliers / Atul Bioscience

Atul Bioscience

India Updated 9 July 2026

Atul Bioscience is an API manufacturer based in India. It holds 8 active US drug master files and 3 valid CEPs across a filed portfolio of 7 molecules. Customs aggregates show $2.7M of exports covering 98 molecules to 16 destinations in 2025.

8
active US DMFs
3
valid CEPs
1
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026.

Registered plants

Site FDA FEI
Ambernath (East), India 3016575313

What they file, and where

Molecule Regulators Docs
Metoprolol SFDA (Saudi Arabia), US FDA 3
Losartan EDQM, US FDA 2
Valaciclovir EDQM, US FDA 2
Venlafaxine EDQM, US FDA 2
Acyclovir US FDA 1
Desvenlafaxine US FDA 1
Fluconazole US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $28K 8
2025 Not reported $2.7M 16
2024 Not reported $2.4M 18
2023 Not reported $2.9M 19

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Atul Bioscience comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts